BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025

Reuters

2025/09/22

BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025

BridgeBio Pharma, Inc. has announced that it will present additional data on the cardiovascular outcomes of Acoramidis from the ATTRibute-CM study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The event will take place in Minneapolis, MN from September 26 - 29, 2025. The presentations will include one late-breaking clinical trials oral presentation by Dr. Ahmad Masri, focusing on the effect of Acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM, scheduled for September 28. Additionally, Dr. Lily Stern will deliver an oral presentation on September 27, highlighting the reduction in risk of all-cause mortality and cardiovascular-related hospitalization with continuous Acoramidis treatment. Several poster sessions are also planned, including the mitigation of NT-proBNP level rises by Acoramidis, presented by Dr. Nitasha Sarswat. These presentations aim to provide further insights into the efficacy and safety of Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9532587-en) on September 22, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2569897527"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2569897527\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2569897527?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569897527","market":"fut","top_or_hot":-1,"title":"BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma, Inc.</a> has announced that it will present additional data on the cardiovascular outcomes of Acoramidis from the ATTRibute-CM study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The event will take place in Minneapolis, MN from September 26 - 29, 2025. The presentations will include one late-breaking clinical trials oral presentation by Dr. Ahmad Masri, focusing on the effect of Acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM, scheduled for September 28. Additionally, Dr. Lily Stern will deliver an oral presentation on September 27, highlighting the reduction in risk of all-cause mortality and cardiovascular-related hospitalization with continuous Acoramidis treatment. Several poster sessions are also planned, including the mitigation of NT-proBNP level rises by Acoramidis, presented by Dr. Nitasha Sarswat. These presentations aim to provide further insights into the efficacy and safety of Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9532587-en) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-22 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/BBIO\">BridgeBio Pharma, Inc.</a> has announced that it will present additional data on the cardiovascular outcomes of Acoramidis from the ATTRibute-CM study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The event will take place in Minneapolis, MN from September 26 - 29, 2025. The presentations will include one late-breaking clinical trials oral presentation by Dr. Ahmad Masri, focusing on the effect of Acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM, scheduled for September 28. Additionally, Dr. Lily Stern will deliver an oral presentation on September 27, highlighting the reduction in risk of all-cause mortality and cardiovascular-related hospitalization with continuous Acoramidis treatment. Several poster sessions are also planned, including the mitigation of NT-proBNP level rises by Acoramidis, presented by Dr. Nitasha Sarswat. These presentations aim to provide further insights into the efficacy and safety of Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9532587-en) on September 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2095319765.USD","symbol_name":"Natixis Thematics Subscription Economy R/A USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250922:nNDL34lcYc:1","article_id":"2569897527","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569897527","pubTimestamp":1758540615,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire  on September 22, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","BK4588":"碎股","BK4585":"ETF&股票定投概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","BK4505":"高瓴资本持仓","BBIO":"BridgeBio Pharma, Inc.","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4139":"生物科技","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"BridgeBio Pharma Inc.在2025年HFSA年度科学会议上宣布了有关Acoramidis对心血管结局影响的新发现","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"BBIO":0.9},"content_text":"BridgeBio Pharma Inc. Announces New Findings on Acoramidis' Impact on Cardiovascular Outcomes at HFSA Annual Scientific Meeting 2025\n    \n\nBridgeBio Pharma, Inc. has announced that it will present additional data on the cardiovascular outcomes of Acoramidis from the ATTRibute-CM study at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025. The event will take place in Minneapolis, MN from September 26 - 29, 2025. The presentations will include one late-breaking clinical trials oral presentation by Dr. Ahmad Masri, focusing on the effect of Acoramidis on recurrent and cumulative cardiovascular outcomes in ATTR-CM, scheduled for September 28. Additionally, Dr. Lily Stern will deliver an oral presentation on September 27, highlighting the reduction in risk of all-cause mortality and cardiovascular-related hospitalization with continuous Acoramidis treatment. Several poster sessions are also planned, including the mitigation of NT-proBNP level rises by Acoramidis, presented by Dr. Nitasha Sarswat. These presentations aim to provide further insights into the efficacy and safety of Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9532587-en) on September 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}